28.74

3.53% 0.98

Rapport Therapeutics Inc (RAPP)

Overview News Price History Discussions Forecast

Rapport Therapeutics Inc stock is traded at $28.74, with a volume of 356.07K. It is up +3.53% in the last 24 hours and up +7.84% over the past month. Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Previous Close:

$27.76

Open:

$27.9

24h Volume:

356.07K

Relative Volume:

0.44

Market Cap:

$1.37B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-2.34%

1M Performance:

+7.84%

6M Performance:

+120.06%

1Y Performance:

+33.30%

1-Day Range:

$27.38

$29.32

1-Week Range:

$26.92

$30.44

52-Week Range:

$7.13

$42.27

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name

Rapport Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

857-321-8020

Address

99 HIGH STREET, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

RAPP's Discussions on Twitter

Compare RAPP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPP Rapport Therapeutics Inc	28.74	1.32B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-25	Initiated	BTIG Research	Buy
Sep-16-25	Initiated	Truist	Buy
Aug-06-25	Initiated	H.C. Wainwright	Buy
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	Jefferies	Buy
Jul-02-24	Initiated	Stifel	Buy
Jul-02-24	Initiated	TD Cowen	Buy

View All

Rapport Therapeutics Inc Stock (RAPP) Latest News

Dec 04, 2025

Will Rapport Therapeutics Inc. stock see PE expansionJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - Newser

Dec 04, 2025

Is Rapport Therapeutics Inc. stock trading at a premium valuationWeekly Market Report & Weekly High Conviction Trade Ideas - Newser

Dec 04, 2025

Dec 03, 2025

(RAPP) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

Dec 03, 2025

Dec 01, 2025

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Dec 01, 2025

Nov 28, 2025

Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? - sharewise.com

Nov 28, 2025

Rapport Therapeutics (RAPP) Is Down 11.3% After Positive Phase 2a Data and $269M Offering – Has the Bull Case Changed? - sahmcapital.com

Nov 28, 2025

Nov 26, 2025

A Look at Rapport Therapeutics’s Valuation as New RAP-219 Phase 2a Data Presentation Approaches - sahmcapital.com

Nov 26, 2025

Nov 25, 2025

How does Rapport Therapeutics Inc (RAPP) change from a tortoise to a hare? - Setenews

Nov 25, 2025

Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)? - simplywall.st

Nov 25, 2025

Rapport Therapeutics to Present New Phase 2a Data Analysis - GlobeNewswire

Nov 25, 2025

Nov 23, 2025

What Analyst Ratings Reveal About Sagar Systech Limiteds Future ValueStock Buy Signals & Fast Growing Trading Plans - earlytimes.in

Nov 23, 2025

Nov 22, 2025

(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Nov 22, 2025

Nov 20, 2025

Can Rapport Therapeutics Inc. stock outperform in 2025 bull marketStop Loss & Long-Term Growth Stock Strategies - newser.com

Nov 20, 2025

Nov 19, 2025

Can trapped investors hope for a rebound in Rapport Therapeutics Inc. - newser.com

Nov 19, 2025

What institutional flow reveals about Rapport Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - newser.com

Nov 19, 2025

Will Rapport Therapeutics Inc. stock pay special dividendsJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com

Nov 19, 2025

This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Nov 19, 2025

Analyzing Rapport Therapeutics Inc. with risk reward ratio chartsTreasury Yields & Safe Capital Growth Tips - newser.com

Nov 19, 2025

BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target - MarketScreener

Nov 19, 2025

BTIG Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq

Nov 19, 2025

What candlestick patterns are forming on Rapport Therapeutics Inc.Gap Up & Verified Entry Point Signals - newser.com

Nov 19, 2025

Why Rapport Therapeutics Inc. stock is a value investor pick2025 Technical Overview & Technical Pattern Based Signals - newser.com

Nov 19, 2025

Nov 18, 2025

Published on: 2025-11-18 22:13:16 - newser.com

Nov 18, 2025

Tools to monitor Rapport Therapeutics Inc. recovery probabilityMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com

Nov 18, 2025

Rapport Therapeutics Executives Sell Shares Under Trading Plans - TradingView

Nov 18, 2025

CEO Ceesay Sells 10,916 ($275K) Of Rapport Therapeutics Inc [RAPP] - TradingView

Nov 18, 2025